Better Therapeutics (NASDAQ:BTTX) announced positive results from its pivotal clinical trial for BT-001, prescription digital therapeutic that is designed to use nCBT to treat c diabetes (T2D).

The secondary endpoint data of the study assessed at day 180 continued this trend, showing statistically significant decreases in A1c levels when compared to a control group receiving standard of care (p-value = 0.01).

Earlier in the month of March, 2022, The company announced that the trial had met its primary endpoint at day 90 with a p-value of < 0.0001.

As the pivotal study is concluded, the company now intends to submit a de novo classification request to the regulatory agency in the third quarter of 2022, seeking marketing authorization for BT-001 for the treatment of patients with T2D.

Price Action : Better Therapeutics shares are trading around 60 percent higher at $2.45 on Thursday during pre-market session.